Control of the lentiviral vector vaccination field
due to a broad & solid intellectual property position
The Pasteur Institute has built a broad and strong patent portfolio covering the use of any gene tranfer vector incorporating the DNA flap sequence. Through our R&D activities and breackthrough discoveries, we aim at further expanding our IP leading position in lentiviral vectors for both human & veterinary vaccination applications.
In 2007, THERAVECTYS & The Pasteur Institute have executed a worldwide exclusive IP licensing agreement
covering the use and the production of lentiviral vectors for vaccination applications
Prophylactic & therapeutic human & veterinary vaccination applications
against all pathologies & pathogens, incl. cancer.
Production & commercialization
of GMP clinical material.
Based on the results generated in our in-house research programs, we are further strenghtening our patent position and are continuously filing new patent applications to protect:
- Every new indication addressed by our vaccine candidates
- Any improvement to the technology platform
In line with our intellectual property strategy, we are building a solid & balanced patent position across multiple geographies including Europe, the U.S., Japan and Australia and protect our innovations over a period of 20 years at least.
This unique IP position in the field of lentiviral vectors put us in a situation to grant our partners sub-licences on the fields secured with Pasteur and/or grant licences to our own patent applications.